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Abstract 
Warfarin is the most widely used medicine
for  oral  anticoagulant  therapy  (OAT).  It
inhibits the synthesis of coagulation factors II,
VII, IX, and X in the liver and results in the pro-
duction of inactive or partially active versions
of these factors. Inactive coagulation factors
interfere with prothrombin time measurement
(Quick and Owren PT) measuring the sum of
coagulation activity and inhibition. The nar-
row therapeutic range here involves a danger
of serious complications and the risk of bleed-
ing  or  thrombosis.  The  new-generation  PT
method can measure coagulation activity and
inhibition separately. This new technique pro-
motes patient care and anticoagulant medica-
tion (warfarin, dicoumarol) based on coagula-
tion activity in vivo. Both therapy and laborato-
ry controls should be unquestionably accurate
and based solely on in vivo coagulation activi-
ty.  Inactive  coagulation  factors  (inhibition)
render measurement, calibration, and harmo-
nization.  The  use  of  the  new-generation  PT
method based on measurement of coagulation
activity in vivo could develop vitamin K antag-
onist (VKA) therapy for the marked benefit of
patients.
History
Discovery of vitamin K antagonists (VKAs)
in anticoagulation occurred in the 1920s, when
the veterinarian Frank Schofield studied the
hemorrhagic disease affecting cattle consum-
ing sweet clover. He ascribed the bleeding to a
toxin in the clover.
1 Karl Link and his team
studied  spoiled  sweet  clover  and,  in  1939,
extracted dicumarol and identified the hemor-
rhagic agent, which was the substance in the
sweet  clover  affecting  coagulation.
2 The  dis-
covery of dicoumarol made it possible to inhib-
it  thrombosis  and  to  study  anticoagulation
therapy for humans in the early 1940s.
3,4 In the
decades  1930  and  1940  Professor  Armand
Quick developed a routine prothrombin time
(PT) coagulation test, which preceded the use
of VKAs.
5,6 This has served as a basis for oral
anticoagulant therapy (OAT) monitoring from
the onset. However this first drug for OAT sub-
sequently was found to have drawbacks by rea-
son of its long half-life. Karl Link
7 synthesized
more than 150 anticoagulant compounds and
found one particularly active molecule, which
was named warfarin (a 4-hydroxy compound)
after the patent holder, the Wisconsin Alumni
Research  Foundation.  Professor  Paul  Owren
found factor V and developed a new PT method
8
subsequent  to  the  “Quick  method”  to  over-
come its drawbacks. The Owren reagent (com-
bined thromboplastin reagent, Thrombotest) is
used mainly in the Nordic countries, Benelux,
and Japan. By reason of its different reagent
composition, the Quick technique is sensitive
to the coagulation factors fibrinogen, II, V, VII,
and X, while the Owren technique is affected by
deficiencies in factors II, VII, and X. The Quick
method  measures  factor  V  and  fibrinogen,
which are not dependent on warfarin therapy,
and this constitutes a drawback for OAT.
Warfarin
The coumarins or VKAs have been the main-
stay of OAT for over 50 years. Warfarin is the
most widely used drug for OAT world-wide, and
it  has  a  predictable  onset  and  duration  of
action and excellent bioavailability. The thera-
py is effective for a variety of clinical indica-
tions of anticoagulation. The dosage and the
clinical  response  still  vary  markedly  among
patients,  depending  on  genetic  inheritance,
age, and metabolism.
Warfarin is a racemic mixture of two opti-
cally active isomers, the R and S forms. It is
rapidly  absorbed  from  the  gastrointestinal
tract (within 90 min) and its half-life is 36-42
h. In the circulation warfarin is bound to plas-
ma proteins (mainly albumin). It accumulates
rapidly in the liver, where it is metabolized.
9
Warfarin interferes with the cyclic intercon-
version of vitamin K and its 2,3 epoxide (vita-
min K epoxide) and thus is a VKA. Vitamin K is
a cofactor in the carboxylation of vitamin K-
dependent  coagulation  factors.  VKA  inhibits
the synthesis of coagulation factors II, VII, IX,
and X in the liver, and they remain partially
inactive unless 9 to 13 of the amino terminal
glutamate (Glu) residues are carboxylated to
form  the  Ca
2+-binding  γ-carboxyglutamate
(Gla)  residues  (Figure  1).
9-11 This  carboxyla-
tion step renders the coagulation factors func-
tionally active: binding to Ca
2+ and the phos-
pholipid surface.
10 Therapeutic dosages of war-
farin decrease, by 30-50%, the total amount of
each vitamin K-dependent coagulation factor
synthesized by the liver. The secreted mole-
cules  from  the  liver  are  under-carboxylated,
resulting in diminished biological activity (10-
40% of normal).
11
Warfarin treatment reduces the number of
Gla residues (normal, 9 to 13) per clotting fac-
tor molecule, with a concomitant fall in coagu-
lant  activity.  When  the  number  of  residues
decreases from 13 to 9, only 70% of the activi-
ty  of  the  clotting  factor  remains;  when  one
molecule contains six carboxylated residues,
only 2% activity is present.
12 The liver excretes
both active and inactive coagulation factors to
the  plasma  and  both  affect  International
Normalized Ratio (INR) measurement,
13 which
possibly  has  escaped  notice  in  the  World
Health Organization (WHO) recommendation
for the prothrombin time methodology.
International Normalized Ratio
The calculation formula is for: INR = (sam-
plesec/normalsec)
ISI,  where  ISI  is  the
International Sensitivity Index. When the ISI is
near 1.0, the reagent is sensitive and ISI has
little meaning in the INR calculation. 
The Quick and Owren PT methods are the
most common and generally accepted means of
monitoring  VKA  therapy.  A  comparison
between the PT methods has been published in
a recent article
14 and the Owren PT was superi-
or. WHO recommends the use of the INR to
harmonize PT results and therapeutic ranges
globally both for patient care in clinical prac-
tice  and  in  the  scientific  literature,  as  the
units  used  formerly  proved  inadequate  for
international  communication.
15,16 The  chal-
lenge is for global clinical laboratories to har-
monize INR testing further to a level where
INR  results  are  consistent  regardless  of  the
methods used.
The use of the INR system still involves diffi-
culties with sample citrate concentration,
17,18dif-
ferent  reagents  and  thromboplastins,
19 and
instruments,
20,21 and with ISI and “local ISI” cal-
ibration
22-28 to harmonize results. Horsti and col-
leagues measured 150 samples from patients on
oral  anticoagulation  using  seven  commercial
reagents  and  four  different  calibrator  kits.
Agreement between INR results was poor.
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ISI calibration
The reagent manufacturer informs the ISI
value or the laboratory can measure the ISI
with an ISI calibration kit (local calibration)
for a PT reagent lot. The meaning of ISI as
power in the INR calculation equation is dis-
played in the previous section. 
First, the aim in the original recommenda-
tion
16,30 was to harmonize INR results by cali-
brating  reagent  ISI  values  with  Human
Combined, which was the primary reference
preparation (IRP code 67/40). Thromboplastins
from different sources (human brain, rabbit
brain, rabbit lung, and ox brain) yield quite dif-
ferent levels of PT. The hierarchy of reference
thromboplastin preparations was presented by
van  den  Besselaar  and  associates.
31 As  the
WHO calibration procedure was complex and
demanding  in  the  second  stage,  the  recom-
mendation for ISI calibration was local calibra-
tion  using  certified  lyophilized  plasmas.
32-37 A
third possible approach for calibration was pre-
sented by van den Besselaar and group. This
alternative  means  of  determining  the  ISI
involves the use of freshly pooled plasmas from
20 normal individuals and 60 patients receiv-
ing coumarin (OAT). Such numbers of samples
are necessary to obtain a precise calibration
line for ISI calculation. Freshly pooled plasma
can be used to determine reagent or instru-
ment ISI with acceptable precision, or as good
a result as with the WHO calibration model.
38
Poller and colleagues (European Concerted
Action on Anticoagulation, ECAA) have com-
pared local ISI calibration and “Direct INR” in
the  correction  for  locally  reported  INRs.  For
local  INR  correction  (harmonization)  they
used  seven  normal  plasmas  and  20  from
patients  on  warfarin.  The  results  were  vari-
able.
39 It is clear that plasmas from patients on
warfarin  therapy  always  involve  varying
amounts  of  inactive  coagulation  factors,
depending on the level of anticoagulation and
individual patient characteristics (see section
on Warfarin). 
All these former calibration models involve
the principle that the calibrator contains an
average amount of inactive coagulation factors
(inhibition), which means an average correc-
tion for patient INR results. Is the average cor-
rection of inactive coagulation factors appro-
priate  for  individual  patient  samples  in  a
measuring range from 1 to 5 INR? Is it a fact
that calibrators, according to biochemical prin-
ciples,  contain  inactive  coagulation  factors
(inhibition)?  Do  different  reagents  behave
identically to active and inactive coagulation
factors?
29 In our earlier studies we measured
inactive  coagulation  factors  (inhibition)  in
four different kits and noted conspicuous vari-
ation in inhibition.
40,41 ISI calibration should be
based on normal plasma and normal plasma
dilutions
42 without  inactive  coagulation  fac-
tors. In principle, calibrators should not con-
tain  inhibitory  coagulation  factors,  which
cause error in calibration.
40
The new-generation prothrom-
bin time method
Today  the  Quick  and  Owren  PT  methods
measure the sum of active coagulation factors
(FII, FVII, FX) and inhibition by their inactive
coagulation factor counterparts. The new-gen-
eration  PT  method  can  measure  separately
both active coagulation factors (FII, FVII, FX)
and the inhibition caused by inactive or par-
tially inactive coagulation factors.
40 Inhibition
varies  markedly  between  individual  patient
samples,  depending  on  the  medication  and
metabolism. Correction of inhibition must be
made individually for each patient sample.
40 In
this method two measurements for one sample
are needed and the cost per sample is twice as
much. The average correction does not suffice
for accurate INR results. In addition, the num-
ber  of  inactive  coagulation  factors  varies
markedly in different calibrator kits (manufac-
tured or local). This means difficulties in cali-
bration  and  harmonization  of  different
reagents.
29,41 The harmonization of INR results
using  different  PT  methods  and  reagents  is
problematic if attempted according to the WHO
recommendation.
29,43 Measuring only the active
coagulation factors without inhibition harmo-
nization between different reagents succeeds
well.
41
Conclusions
New medications for OAT have been devel-
oped over a number of years and anticipated
Article
Figure 1. The enzyme reactions involved in the metabolic function of vitamin K. Vitamin
K-dependent carboxylase catalyzes the transformation of peptide- (Factors II, VII, IX, and
X) bound glutamate residues (Glu) to γ-carboxyglutamate (Gla) residues in the presence
of vitamin K hydroquinone, carbon dioxide, and molecular oxygen (I). Vitamin K hydro-
quinone is oxidized in the reaction to vitamin K 2,3 epoxide. The reduction of the latter
to vitamin K quinone is catalyzed by vitamin K epoxide reductase, which can use certain
dithiols as the reductants (II). Vitamin K quinone can be reduced to vitamin K hydro-
quinone in the reactions catalyzed by either a dithiol-dependent (III) or an NAD(H)P-
dependent (IV) entzyme. Warfarin (WARF) blocks reactions II and III. (Uotila L. Recent
findings on the functions and requirements of vitamin K in humans. Klinlab 1998;3:97-
101.)[Hematology Reviews 2009; 1:e19] [page 101]
without laboratory test control in an effort to
displace warfarin medication. The new medi-
cines, however, have not proved their superior-
ity over warfarin. The new molecules are too
expensive  for  global  use  or  involve  serious
side-effects and possibly will never be as popu-
lar  as  warfarin,  which  is  an  old  and  cheap
means widely used and accepted globally. The
only drawback with warfarin medication is reg-
ular laboratory control. It would be important to
develop warfarin therapy with greater atten-
tion to laboratory control, which helps patient
care. Different reagents and thromboplastins
react variably with inactive coagulation factors
and  cause  difficulties  in  calibration  using
patient plasmas that contain inhibiting coagu-
lation  factors.  Data  on  inactive  coagulation
factors are individual and should be corrected
individually. Every new anticoagulant therapy
patient should be tested for inhibition at the
commencement of therapy.
The accuracy and harmonization of patient
INR  results  for  different  reagents  is  of  the
utmost importance for scientific publications,
medication, and patient care. Today’s measur-
ing principle is taking the sum of active coag-
ulation factors (FII, FVII, FX), and inhibition of
inactive coagulation factors is not a satisfacto-
ry approach from the standpoint of accurate
patient care. Active coagulation factors in vivo
are responsible for thrombosis and bleeding.
The  errors  in  INRs  are  too  great,  which  in
many ways affects the success of medication
and  patient  well-being,  also  using  the  same
calibration (local calibration).
29 The new-gen-
eration PT offers possibilities of more accurate
INR results and patient care based on control
of  active  coagulation  factors.  The  inhibition
renders measurement, calibration, and harmo-
nization.
29,40,41 The  therapeutic  INR  ranges
guiding  anticoagulant  therapy  using  “old
methods” are based on the principle that both
calibrators and patient samples have inactive
coagulation  factors  (inhibition)  on  average,
which compensate for each other in the final
INR result. Thus the therapeutic ranges are
available for the new-generation PT method.
The therapeutic range lies between thrombo-
sis and bleeding, and complications are seri-
ous and general.
44 The medication and care of
OAT patients must be rendered better and safe
using a more sensitive PT test.
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